Diffuse Large B Cell Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 54 expanded access programs, clinical trials, and compassionate use pathways listed for Diffuse Large B Cell Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with diffuse large b cell lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 48 programs are currently active or recruiting, with the remaining 6 in other lifecycle stages. Sponsors actively running programs in this area include Genmab, Hoffmann-La Roche, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), Barbara Ann Karmanos Cancer Institute, and others.
By recruiting status
Snapshot of where every Diffuse Large B Cell Lymphoma program currently sits in its lifecycle.
- Active / Recruiting48
- Inactive6
Top sponsors
Organisations running the most Diffuse Large B Cell Lymphoma programs in the directory.
- Genmab6 programs
- Hoffmann-La Roche3 programs
- Merck Sharp & Dohme LLC3 programs
- National Cancer Institute (NCI)3 programs
- Barbara Ann Karmanos Cancer Institute2 programs
- Incyte Corporation2 programs
- New York Medical College2 programs
- Acerta Pharma BV1 program
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1 program
- AstraZeneca1 program
Diffuse Large B Cell Lymphoma programs (54)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Acalabrutinib Combined with R-CHOP for Untreated Non-GCB Diffuse Large B-Cell Lymphoma — Acerta Pharma BV
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- Long-term Study of Ibrutinib for Ongoing Access and Safety Monitoring — Janssen Research & Development, LLC
- Phase 3 Study Comparing Epcoritamab to Chemotherapy in Patients with Difficult-to-Treat Diffuse Large B-cell Lymphoma (DLBCL) — Genmab
- Phase III Study Comparing Glofitamab with Gemcitabine and Oxaliplatin to Rituximab with Gemcitabine and Oxaliplatin for Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Study on Brentuximab Vedotin, Rituximab, and Modified CHP for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — Patrick Reagan
- Study of CPI-0209 for Patients with Advanced Solid Tumors and Lymphomas — Constellation Pharmaceuticals
- Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Study Comparing Epcoritamab and Lenalidomide to Rituximab, Gemcitabine, and Oxaliplatin in Adults with Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma — Genmab
- Study of Zilovertamab Vedotin with Standard Treatment for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) — Merck Sharp & Dohme LLC
- Study on the Safety of Epcoritamab for Adults with Returning or Hard-to-Treat Large B-Cell and Follicular Lymphoma — Genmab
- Study on Optimizing Cytokine Release Syndrome for Glofitamab with Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Study Comparing Zilovertamab Vedotin with Standard Treatment for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) — Merck Sharp & Dohme LLC
- Study on Acalabrutinib Maintenance for Treating Large B-cell Lymphoma — Jonsson Comprehensive Cancer Center
- Study on Acalabrutinib with DA-EPOCH-R or R-CHOP for Untreated Diffuse Large B-cell Lymphoma — National Cancer Institute (NCI)
- Study on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma — New York Medical College
- Study on Brentuximab Vedotin with Lenalidomide and Rituximab for Treating Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma — Seagen, a wholly owned subsidiary of Pfizer
- Study on CAR-20/19-T Cells for Patients with Hard-to-Treat B Cell Cancers — Medical College of Wisconsin
- Preventing CNS Relapse in High-Risk Diffuse Large B-cell Lymphoma with Thiotepa-based Stem Cell Transplant — Washington University School of Medicine
- Study on Copanlisib and Venetoclax for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Dana-Farber Cancer Institute
- Study on Emapalumab to Prevent Side Effects from CAR-T Cell Therapy in Non-Hodgkin's Lymphoma Patients — Marcela V. Maus, M.D.,Ph.D.
- Study on Itacitinib Before CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — H. Lee Moffitt Cancer Center and Research Institute
- Local Production of CAR T-Cell Therapy for Treating B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — John Lister
- Study on Mosunetuzumab and Chemotherapy for Untreated High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma with C-Myc Rearrangement — OHSU Knight Cancer Institute
- Study on Obinutuzumab and ICE Chemotherapy for Difficult or Returning CD20+ Non-Hodgkin Lymphoma — New York Medical College
- Study on Pembrolizumab and Chemotherapy for Untreated B Cell Lymphoma — University of Chicago
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, Advanced DLBCL, ALL, and High-Risk LBCL — Novartis Pharmaceuticals
- Study on Polatuzumab Vedotin and Combination Chemotherapy for Treating Untreated Lymphoma — Barbara Ann Karmanos Cancer Institute
- Study on Rituximab, Lenalidomide, Acalabrutinib, and Tafasitamab with Chemotherapy for Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma — M.D. Anderson Cancer Center
- Study on the Safety and Effectiveness of KRT-232 with Acalabrutinib for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia — Kartos Therapeutics, Inc.
- Safety and Effectiveness Study of Epcoritamab Combinations for B-cell Non-Hodgkin Lymphoma — Genmab
- Study on the Safety and Effects of a New Dosing Schedule for Tafasitamab with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Incyte Corporation
- Study on Selinexor for Patients with Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma (DLBCL) — Karyopharm Therapeutics Inc
- Study on Selinexor with Chemotherapy for Treating Advanced B Cell Non-Hodgkin Lymphoma — Barbara Ann Karmanos Cancer Institute
- Split-Dose R-CHOP Chemotherapy for Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) — University of Wisconsin, Madison
- Study on Acalabrutinib and Rituximab for Untreated Elderly and/or Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — AstraZeneca
- Study on IOMAB-ACT and CAR-T Cell Therapy for Patients with Difficult or Returning Diffuse Large B-cell Lymphoma — University of Texas Southwestern Medical Center
- Study of Iopofosine I 131 (CLR 131) for Certain B-Cell Blood Cancers and Waldenstrom Macroglobulinemia — Cellectar Biosciences, Inc.
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Study on Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors — Merck Sharp & Dohme LLC
- Study Comparing Tafasitamab, Lenalidomide, and R-CHOP with R-CHOP Alone in Newly Diagnosed High-Risk DLBCL Patients — Incyte Corporation
- Study on Tafasitamab, Retifanlimab, and Rituximab with Standard Therapy for Treating Diffuse Large B-cell Lymphoma — University of Washington
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed or Hard-to-Treat Diffuse Large B-cell Lymphoma — SWOG Cancer Research Network
- Study on Adding Venetoclax to Usual Chemotherapy for High-Grade B-Cell Lymphomas — National Cancer Institute (NCI)
- Study on Venetoclax Plus R-ICE Chemotherapy for Difficult or Returning Diffuse Large B-Cell Lymphoma — Molly Gallogly
- Study on Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) for Treating B-cell Lymphoma That Has Returned or Not Improved — National Cancer Institute (NCI)
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation — University of Michigan Rogel Cancer Center
- Study on Zanubrutinib for Patients with DLBCL and Specific Genetic Mutations or CD5+ — Virginia Commonwealth University
- Study Comparing Polatuzumab Vedotin with R-CHP and R-CHOP in Patients with Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Study on Epcoritamab with R-CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Genmab
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. — Pfizer
- Study on Polatuzumab Vedotin with R-GDP for Treating Relapsed or Hard-to-Treat Diffuse Large B-cell Lymphoma — UNC Lineberger Comprehensive Cancer Center
- Study on E7777 Before Kymriah for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Masonic Cancer Center, University of Minnesota
- Study on Subcutaneous Epcoritamab With or Without Lenalidomide as First Treatment for Diffuse Large B-Cell Lymphoma — Genmab
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Diffuse Large B Cell Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.